Goldline Pharmaceutical IPO Subscription Status
The Goldline Pharmaceutical IPO has been subscribed 781.85x times overall. Retail investors have shown interest with bids for 881.15x the shares available. The Non-Institutional Investor (NII) category has been subscribed 1227.9x. Within NII, Big HNI (B-HNI) subscribed 2011.14x and Small HNI (S-HNI) subscribed 980.75x. Qualified Institutional Buyers (QIBs) have subscribed 180.22x. Data last updated on 03 Sep, 02:08 PM.
The IPO subscription period has ended. Given the strong demand, the allotment process is expected to be highly competitive. The issue opened on 12 May, 2026 and closes on 14 May, 2026. The shares are expected to list on stock exchanges on 19 May, 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Live bidding
Shares bid against shares offered, category by category, as published by the exchanges. Switch to Detailed for the exchange's own sub-category rows.
| Category | Bid details | Times |
|---|---|---|
| QIB | 9,73,17,000 of 5,40,000 | 180.22x |
| NII | 64,83,33,000 of 5,28,000 | 1227.9x |
| Retail | 79,30,38,000 of 9,00,000 | 881.15x |
| TOTAL | 1,53,86,88,000 | 781.85x |
Application-wise breakup (estimated)
Approximate application counts — the exchanges don't publish these during bidding. Estimated from shares bid using the typical application size seen in recent IPOs' Basis of Allotment data. Final counts appear here once the Basis of Allotment is out.
| Category | Est. Applied | Times | |
|---|---|---|---|
| Retail max 286 | 1,32,173 | 462.14x | |
| sNII (₹2–10 L) max 21 | 13,504 | 643.05x | |
| bNII (₹10 L+) max 10 | 16,153 | 1,615.30x | |
| TOTAL (EST.) | 1,61,830 |
Subscription insights
What the current book is saying, read off the category numbers above.
Retail Allotment
High demand detected. The retail category is heavily oversubscribed, making the allotment a lottery where only 1 out of every 882 applicants will be successful.
Institutional Backing
Massive institutional interest with QIBs subscribing 180.22x. This often signals long-term confidence from professional funds.
Day-wise subscription history
End-of-day subscription across the 3-day bidding window. On phones, tap a day for the category split.
| Date | Total | ||
|---|---|---|---|
|
14 May 2026
Day 3 |
781.85x | ▼ | |
|
QIB180.22x
NII1227.9x
Retail881.15x
|
|||
|
13 May 2026
Day 2 |
93.19x | ▼ | |
|
QIB1.31x
NII108.19x
Retail139.51x
|
|||
|
12 May 2026
Day 1 |
20.79x | ▼ | |
|
QIB1.31x
NII18.07x
Retail34.07x
|
|||
Goldline Pharmaceutical SME IPO dates
From the bidding window to listing. Today is 20 September.
- Open 12 May 2026
- Close 14 May 2026
- Allotment 15 May 2026
- Refund/credit 18 May 2026
- Listing 19 May 2026
Goldline Pharmaceutical IPO allotment probability
Your odds of an allotment in each category at the current subscription.
Odds marked with applicant counts are computed from the exchange's actual application data (applicants ÷ allotment slots); others assume minimum-size bids at the current subscription multiple. Retail and HNI allotment is by SEBI-mandated lottery of the minimum application when oversubscribed; QIB allotment is proportionate. Numbers move until subscription closes. This is not investment advice.
What does this subscription data mean?
IPO subscription data tells you how much demand exists for the shares being offered, broken down by investor category. Understanding each category helps you gauge the real sentiment behind the numbers:
- 01 QIB (Qualified Institutional Buyers) — includes mutual funds, FIIs, insurance companies, and banks. QIBs do deep due diligence before bidding. A QIB subscription above 10x is a strong institutional endorsement. Watch QIB numbers closely on the final day — they often hold back and flood in after 3 PM.
- 02 NII / HNI (Non-Institutional Investors) — high-net-worth individuals bidding above ₹2 lakh. NII allotment is proportionate (not lottery), so higher NII subscription means smaller per-lot allotment. Big HNI (B-HNI) bids above ₹10 lakh; Small HNI (S-HNI) bids ₹2–10 lakh.
- 03 Retail — individual investors bidding up to ₹2 lakh. When retail is below 1x, everyone who applied gets full allotment. When oversubscribed, SEBI mandates a computerised lottery — only 1 lot per successful applicant regardless of how many lots you apply for.
- 04 Overall Subscription — a blended multiple across all categories. A total subscription above 10x is considered strong; above 50x is exceptional and usually predicts strong listing gains.
Data sourced from BSE/NSE. Subscription numbers are updated during market hours (10 AM – 5 PM IST) on active subscription days.
Frequently asked
What is the current subscription status of Goldline Pharmaceutical IPO?
As of IPO close date (14 May, 2026), the Goldline Pharmaceutical IPO is subscribed 781.85x times. Retail category is 881.15x, and NII is 1227.9x subscribed.
When is the allotment date for Goldline Pharmaceutical IPO?
The allotment for Goldline Pharmaceutical IPO is expected to be finalized on 15 May, 2026.
What is the GMP of Goldline Pharmaceutical?
The Grey Market Premium (GMP) for Goldline Pharmaceutical is currently ₹15, indicating a potential listing gain of 35%.
When will Goldline Pharmaceutical IPO list on the stock market?
Goldline Pharmaceutical is scheduled to list on BSE and NSE on 19 May, 2026.
What are the chances of getting allotment in Goldline Pharmaceutical IPO?
The retail category is oversubscribed at 881.15x, meaning allotment is by lottery. Statistically, approximately 1 in 882 applicants will receive allotment. Applying with multiple family member accounts (each at minimum lot size) improves your cumulative odds.
What does QIB subscription of 180.22x mean for Goldline Pharmaceutical IPO?
Strong — QIBs (mutual funds, FIIs, insurance companies) have subscribed 180.22x, indicating high institutional conviction. Heavy QIB demand is historically one of the strongest predictors of a positive listing.
How to check Goldline Pharmaceutical IPO allotment status?
After the allotment date (15 May, 2026), you can check your Goldline Pharmaceutical IPO allotment status on IPO Guru's allotment checker, on the BSE/NSE website using your PAN or application number, or through your broker's app.
Explore Goldline Pharmaceutical SME IPO further
Track every stage of this IPO, from subscription to listing.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
Subscription moves by the hour. Get it on your phone.
Live GMP alerts, subscription updates and allotment status for every Mainboard and SME issue — fast, free and secure.
Not investment advice. Subscription figures are as published by BSE/NSE and change until bidding closes.
